By ANDREW POLLACK
J. Michael Pearson has been struggling to reassure investors as Valeant faces concerns about its pricing and distribution policies for its drugs.
Published: December 26, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1miIHcP
from WordPress http://ift.tt/1ZtAKzT
via Hadi Aboukhater
No comments:
Post a Comment